Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Marina, Čakš"'
Autor:
Erika Matos, Snežana Đokić, Srdjan Novaković, Marina Čakš, Rok Devjak, Nežka Hribernik, Kaja Cankar
Publikováno v:
Onkologija, Vol 28, Iss 1 (2024)
Rak neznanega izvora (RNI) je opredeljen kot karcinom ali nediferencirana neoplazma, pri kateri z naborom standardnih diagnostičnih postopkov ni mogoče odkriti izvornega mesta bolezni. Tradicionalno RNI delimo v dve podskupini, pri čemer le pribli
Externí odkaz:
https://doaj.org/article/35c287721c644600a2a2020d3dd09923
Autor:
Martina Vrankar, Nina Boc, Izidor Kern, Aleš Rozman, Karmen Stanič, Tomaž Štupnik, Mojca Unk, Maja Ebert Moltara, Vesna Zadnik, Katja Adamič, Jernej Benedik, Marko Bitenc, Jasna But Hadžić, Anton Crnjac, Marina Čakš, Dominik Časar, Eva Ćirić, Tanja Čufer, Ana Demšar, Rok Devjak, Goran Gačevski, Marta Globočnik Kukovica, Kristina Gornik Kramberger, Maja Ivanetič Pantar, Marija Ivanovič, Urška Janžič, Staša Jelerčič, Veronika Kloboves Prevodnik, Mile Kovačevič, Luka Ležaić, Mateja Marc Malovrh, Katja Mohorčič, Loredana Mrak, Igor Požek, Nina Turnšek, Bogdan Vidmar, Dušanka Vidovič, Gregor Vlačič, Ana Lina Vodušek, Rok Zbačnik, Ivana Žagar
Publikováno v:
Onkologija, Vol 27, Iss 1 (2023)
In 2019, the Recommendations for the management of patients with lung cancer were published bringing much-needed standardisation of diagnosis and treatment to improve survival of patients with lung cancer. Three years after the original Recommendatio
Externí odkaz:
https://doaj.org/article/3b1270e9772f48a88ef104c12d74f549
Autor:
ANJA KOVAČ, Erika Matos, Cvetka Grašič Kuhar, Marina Čakš, Tanja Ovčariček, Marina Mencinger, Mojca Humar, Simona Borštnar
Publikováno v:
Cancer Treatment and Research Communications, Vol 25, Iss , Pp 100201- (2020)
Background: Selective cyclin-dependent kinases 4/6 inhibitors (CDKi) have become the standard of care in patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancer (ABC). We performed retrospective analysis in patients treated
Externí odkaz:
https://doaj.org/article/c7467637b3a9492d8d06b04ddfa13ccb
Autor:
Martina, Vrankar, Nina, Boc, Izidor, Kern, Aleš, Rozman, Karmen, Stanič, Tomaž, Štupnik, Mojca, Unk, Maja, Ebert Moltara, Vesna, Zadnik, Katja, Adamič, Jernej, Benedik, Marko, Bitenc, Jasna, But Hadžić, Anton, Crnjac, Marina, Čakš, Dominik, Časar, Eva, Ćirić, Tanja, Čufer, Ana, Demšar, Rok, Devjak
Publikováno v:
Onkologija; jun2023, Vol. 27 Issue 1, p30-44, 15p
Autor:
Marina Čakš, Tanja Ovcaricek, Simona Borštnar, Mojca Humar, Erika Matos, Anja Kovač, Marina Mencinger, Cvetka Grašič Kuhar
Publikováno v:
Cancer Treatment and Research Communications, Vol 25, Iss, Pp 100201-(2020)
Background Selective cyclin-dependent kinases 4/6 inhibitors (CDKi) have become the standard of care in patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancer (ABC). We performed retrospective analysis in patients treated